Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Eli Lilly Commits $50M to UNICEF USA Alliance Targeting Non-Communicable Disease Prevention in Children Across 21 LMICs

Fineline Cube May 15, 2026
Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Company Deals

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Fineline Cube May 13, 2026
Policy / Regulatory

China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations

Fineline Cube May 15, 2026
Company Drug

Amgen’s Izervay NDA Accepted by NMPA for Geographic Atrophy Secondary to Age-Related Macular Degeneration

Fineline Cube May 15, 2026
Company Drug

Chongqing Genrix Bio Receives NMPA Clinical Approval for GR1803 Bispecific Antibody in Relapsed/Refractory Multiple Myeloma

Fineline Cube May 15, 2026
Company Deals

Youwe Bio’s Series B Financing to Advance Microneedle Technology Commercialization

Fineline Cube Jun 30, 2022

China-based Youwe (Zhuhai) Biotechnology Co., Ltd, a developer of soluble microneedle transdermal drug delivery technology,...

Policy / Regulatory

NHSA Updates NRDL with Focus on Expert Review and Simplified Renewals

Fineline Cube Jun 30, 2022

The National Healthcare Security Administration (NHSA) has released the “2022 National Reimbursement Drug List (NRDL)...

Company Drug

Ascletis Pharma Doses First Patient in China’s Phase II Trial for HIV-1 Treatment with ASC22

Fineline Cube Jun 29, 2022

China-based Ascletis Pharma Inc. (HKG: 1672) announced the dosing of the first patient in its...

Company Drug

Jixing Pharmaceuticals’ Aficamten Receives CDE Approval for Phase III HCM Study

Fineline Cube Jun 29, 2022

China-based Ji Xing Pharmaceuticals announced receiving approval from the Center for Drug Evaluation (CDE) to...

Company Drug

BDgene Advances CRISPR-Based BD111 for Herpes Keratitis with IND Filing

Fineline Cube Jun 29, 2022

Shanghai BDgene Technology Co., Ltd has completed efficacy and preliminary safety studies for BD111, its...

Company Deals

MicroPort NeuroTech Lists in Hong Kong with $43.3 Million IPO

Fineline Cube Jun 29, 2022

MicroPort NeuroTech Limited has successfully completed its initial public offering (IPO) on the Hong Kong...

Company Drug

Bayer’s Kerendia Approved by China’s NMPA for Diabetic Kidney Disease

Fineline Cube Jun 29, 2022

The National Medical Products Administration (NMPA) has approved Bayer’s (ETR: BAYN) Category 1 drug Kerendia...

Company Drug

Hengrui Medicine’s SHR3680 Approved for High Burden Metastatic Prostate Cancer

Fineline Cube Jun 29, 2022

China’s Hengrui Medicine Co., Ltd. (SHA: 600276) announced that its Category 1 drug SHR3680 has...

Company Deals R&D

Legend Biotech Collaborates with Trinity College Dublin on CAR-T Therapies for Solid Tumors

Fineline Cube Jun 29, 2022

China-based Legend Biotech Corporation (NASDAQ: LEGN) has formed a partnership with Trinity College Dublin and...

Company Deals

AnchorDx and West China Hospital Collaborate on Lung Cancer Early Diagnosis

Fineline Cube Jun 29, 2022

Guangzhou-based AnchorDx and West China Hospital of Sichuan University have entered into a transfer agreement...

Company Drug

Akeso Biopharma’s Cadonilimab Approved for Cervical Cancer Treatment

Fineline Cube Jun 29, 2022

China-based biotech company Akeso Biopharma (HKG: 9926) announced that its self-discovered bispecific antibody (BsAb) cadonilimab...

Company Drug

Humanwell Healthcare Wins NMPA Approval for RFUS-144 in Pain Management

Fineline Cube Jun 29, 2022

China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced receiving approval from the National Medical...

Company Deals

LaNova Medicines Secures Series B Funding to Advance Oncology Pipeline

Fineline Cube Jun 29, 2022

China-based LaNova Medicines has successfully closed a Series B financing round, raising an undisclosed sum...

Company Deals

GenFleet Collaborates with BioLineRx to Develop Motixafortide for Pancreatic Cancer in China

Fineline Cube Jun 29, 2022

China-based GenFleet Therapeutics has entered into a collaboration with Israel’s BioLineRx Ltd (NASDAQ: BLRX) to...

Company Deals

Henlius and Palleon Partner on HER2-Targeted Antibody-Sialidase Fusion Protein

Fineline Cube Jun 29, 2022

China-based Shanghai Henlius Biotech Inc. (HKG: 2696) announced a strategic partnership with US-based Palleon Pharmaceuticals...

Company R&D

Lundbeck Initiates TALISMAN Study on Multiple System Atrophy in China and EU

Fineline Cube Jun 28, 2022

Danish-based Lundbeck (OTCMKTS: HLUBF) has announced plans to initiate a global investigational study on multiple...

Company Deals

OCON Healthcare Partners with Bio Genuine for China Marketing Rights and Women’s Health Product Development

Fineline Cube Jun 28, 2022

Israel-based OCON Healthcare, a specialist in uterine drug delivery, has entered into a license agreement...

Company Deals

Expeclinlab Raises RMB 185 Million to Boost Clinical Mass Spectrometry Business

Fineline Cube Jun 28, 2022

Focused Photonics Inc’s (SHE: 300203) subsidiary Expeclinlab has secured RMB 185 million (USD 27.7 million)...

Company Deals

Beijing Luzhu Biotechnology Secures Series C Funding for Meningococcal Vaccine Development

Fineline Cube Jun 28, 2022

China-based Beijing Luzhu Biotechnology Co., Ltd has reportedly secured an undisclosed amount in a Series...

Company Drug

Eli Lilly’s Donanemab Receives Tacit Approval for Alzheimer’s Clinical Trial in China

Fineline Cube Jun 28, 2022

The Center for Drug Evaluation (CDE) website indicates that US major Eli Lilly’s (NYSE: LLY)...

Posts pagination

1 … 657 658 659 … 666

Recent updates

  • Alibaba Health Reports Strong FY2026 Results with 35.2% Profit Growth and Launches Medical LLM “H+”
  • Amgen’s Izervay NDA Accepted by NMPA for Geographic Atrophy Secondary to Age-Related Macular Degeneration
  • China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations
  • Chongqing Genrix Bio Receives NMPA Clinical Approval for GR1803 Bispecific Antibody in Relapsed/Refractory Multiple Myeloma
  • AstraZeneca Reports Positive Phase III VOLGA Interim Results for Imfinzi-Based Combinations in Muscle-Invasive Bladder Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Digital

Alibaba Health Reports Strong FY2026 Results with 35.2% Profit Growth and Launches Medical LLM “H+”

Company Drug

Amgen’s Izervay NDA Accepted by NMPA for Geographic Atrophy Secondary to Age-Related Macular Degeneration

Policy / Regulatory

China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations

Company Drug

Chongqing Genrix Bio Receives NMPA Clinical Approval for GR1803 Bispecific Antibody in Relapsed/Refractory Multiple Myeloma

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.